To review the currently available information on atovaquone–proguanil for treatment and prophylaxis of malaria.
DATA SOURCES:
A MEDLINE search was conducted from 1966 to February 2003 using key phrases Malarone, atovaquone, proguanil, and malaria. Further articles were identified from a manual search of the references of identified articles.
STUDY SELECTION AND DATA EXTRACTION:
English-language studies with animal and human data evaluating preclinical pharmacology, human studies on pharmacokinetics, and clinical trials were evaluated. Relevant data were extracted from identified articles.
DATA SYNTHESIS:
Atovaquone–proguanil has been evaluated for treatment of acute, uncomplicated malaria caused by Plasmodium falciparum in 8 clinical trials. In these studies, treatment with atovaquone–proguanil led to a higher (87–100% vs. 72–88%) or equally effective (94–100% vs. 90–100%) cure rate than the comparator antimalarial agents. Atovaquone–proguanil has been evaluated for prophylaxis of malaria in 6 clinical trials. In the 4 placebo-controlled trials for semi-immune residents or nonimmune migrants, the prophylaxis success rates in the atovaquone–proguanil and placebo arms ranged from 98% to 100% and 48% to 82%, respectively. The prophylaxis with success rates were similar among the 2 arms when atovaquone–proguanil was compared with other antimalarial regimens in nonimmune travelers. Atovaquone–proguanil was well tolerated in these clinical trials.
CONCLUSIONS:
Atovaquone–proguanil is a safe and effective alternative to current recommended regimens for prophylaxis and treatment of malaria.
SchwartlanderB. Global burden of disease. Lancet1997; 350: 141–2.
2.
SnowRWTrapeJFMarshK. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol2001; 17: 593–7.
3.
SnowRWCraigMDeichmannUMarshK. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull World Health Org1999; 77: 624–40.
4.
PhillipsRS. Current status of malaria and potential for control. Clin Microbiol Rev2001; 14: 208–16.
5.
Package insert. Malarone (atovaquone and proguanil hydrochloride). Research Triangle Park, NC: GlaxoSmithKline, August 2002.
6.
SunILSunEECraneFLMorreDJLindgrenALowH. Requirement for coenzyme Q in plasma membrane electron transport. Proc Natl Acad Sci USA1992; 89: 11126–30.
7.
FryMPudneyM. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol1992; 43: 1545–53.
8.
SrivastavaIKVaidyaAB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother1999; 43: 1334–9.
9.
HammondDJBurchellJRPudneyM. Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. Mol Biochem Parasitol1985; 14: 97–109.
10.
Atovaquone/proguanil (Malarone) for malaria. Med Lett Drugs Ther2000; 42: 109–11.
11.
SabchareonAAttanathPPhanuaksookPChanthavanichPPoonpanichYMookmaneeD, Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg1998; 92: 201–6.
12.
ThaparMMAshtonMLindegardhNBergqvistYNiveliusSJohanssonI, Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol2002; 58: 19–27.
13.
GillotinCMametJPVeroneseL. Lack of a pharmacokinetic interaction between atovaquone and proguanil. Eur J Clin Pharmacol1999; 55: 311–5.
14.
EdsteinMDLooareesuwanSViravanCKyleDE. Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. Southeast Asian J Trop Med Public Health1996; 27: 216–20.
15.
HusseinZEavesJHutchinsonDBCanfieldCJ. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin Pharmacol Ther1997; 61: 518–30.
16.
HusseinZEavesCJHutchinsonDBCanfieldCJ. Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. Br J Clin Pharmacol1996; 42: 589–97.
17.
van VugtMEdsteinMDProuxSLayKOohMLooareesuwanS, Absence of an interaction between artesunate and atovaquone–proguanil. Eur J Clin Pharmacol1999; 55: 469–74.
RadloffPDPhilippsJNkeyiMHutchinsonDKremsnerPG. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet1996; 347: 1511–4.
20.
de AlencarFCeruttiCJrDurlacherRRBoulosMAlvesFPMilhousW, Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis1997; 175: 1544–7.
21.
LooareesuwanSWilairatanaPChalermarutKRattanapongYCanfieldCJHutchinsonDB. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg1999; 60: 526–32.
22.
MulengaMSukwaTYCanfieldCJHutchinsonDB. Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia. Clin Ther1999; 21: 841–52.
23.
AnabwaniGCanfieldCJHutchinsonDB. Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children. Pediatr Infect Dis J1999; 18: 456–61.
24.
BustosDGCanfieldCJCanete-MiguelEHutchinsonDB. Atovaquone-proguanil compared with chloroquine and chloroquine–sulfadoxine–pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis1999; 179: 1587–90.
25.
BouchaudOMonlunEMuanzaKFontanetAScottTGoetschelA, Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial. Am J Trop Med Hyg2000; 63: 274–9.
26.
Llanos-CuentasACamposPClendenesMCanfieldCJHutchinsonDB. Atovaquone and proguanil hydrochloride compared with chloroquine or pyrimethamine/sulfodaxine for treatment of acute Plasmodium falciparum malaria in Peru. Braz J Infect Dis2001; 5: 67–72.
27.
LooareesuwanSWilairatanaPGlanarongranRIndravijitKASupeeranonthaLChinnaphaS, Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans R Soc Trop Med Hyg1999; 93: 637–40.
28.
BermanJDNielsenRChulayJD, Causal prophylactic efficacy of atovaquone–proguanil (Malarone) in a human challenge model. Trans R Soc Trop Med Hyg2001; 95: 429–32.
29.
ShanksGDGordonDMKlotzFWAlemanGMOlooAJSadieD, Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis1998; 27: 494–9.
30.
LellBLucknerDNdjaveMScottTKremsnerPG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet1998; 351: 709–13.
31.
SukwaTYMulengaMChisdakaNRoskellNSScottTR. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg1999; 60: 521–5.
32.
HoghBClarkePDCamusDNothdurftHDOverboschDGuntherM, Atovaquone–proguanil versus chloroquine–proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. Lancet2000; 356: 1888–94.
33.
OverboschDSchilthuisHBienzleUBehrensRHKainKCClarkePD, Atovaquone–proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis2001; 33: 1015–21.
34.
LingJBairdJKFryauffDJSismadiPBangsMJLacyM, Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis2002; 35: 825–33.
35.
Canadian recommendations for the prevention and treatment of malaria among international travellers. Can Commun Dis Rep2000; 26S2: 1–42.
36.
Health information for international travel 2001–2002. Atlanta: Centers for Disease Control and Prevention, 2001.
37.
International travel and health. Geneva: World Health Organization, 2002.
38.
NostenFBrasseurP. Combination therapy for malaria. The way forward. Drugs2002; 62: 1315–29.
39.
LobelHOPhillips-HowardPABrandling-BennettADSteffenRCampbellCCHuongAY, Malaria incidence and prevention among European and North American travelers to Kenya. Bull World Health Org1990; 68: 209–15.
40.
SteffenR. Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy. Bull World Health Org1990; 68: 313–22.
